Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus
| Autor: | Sara Baqar, Georgina Thomas, Elisabeth Lambert, Christopher O'Callaghan, Elif I Ekinci, Gowri Somarajah, George Jerums, Richard J MacIsaac, Angela Xun-Nan Chen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Type 2 diabetes Plasma renin activity Benzoates Renin-Angiotensin System chemistry.chemical_compound Hydrochlorothiazide Double-Blind Method Internal medicine Diabetes mellitus Renin–angiotensin system Renin medicine Humans Arterial Pressure Telmisartan Sodium Chloride Dietary Antihypertensive Agents Aged Aldosterone Cross-Over Studies business.industry General Medicine Middle Aged medicine.disease Angiotensin II Endocrinology Treatment Outcome chemistry Diabetes Mellitus Type 2 Hypertension Benzimidazoles Female business Angiotensin II Type 1 Receptor Blockers Biomarkers medicine.drug |
| Zdroj: | Clinical science (London, England : 1979). 129(5) |
| ISSN: | 1470-8736 |
| Popis: | Current guidelines recommend low dietary salt intake (LDS) in patients with diabetes to reduce blood pressure (BP). However, low salt intake has been associated with higher mortality rates in people with diabetes. Our aim is to examine the effect of angiotensin II receptor blocker (ARB), telmisartan, with and without dietary sodium chloride (NaCl) supplementation, on BP [mean arterial pressure (MAP)], plasma renin activity (PRA), serum aldosterone level and estimated glomerular filtration rate (eGFR) in hypertensive patients with type 2 diabetes. In a randomized, double-blind, placebo-controlled study (RCT), 28 patients with type 2 diabetes, treated with telmisartan (40 mg daily), received 2 weeks of placebo or NaCl capsules (100 mmol/24 h). Following a 6-week washout, the protocol was repeated in reverse. Twenty-four-hour urinary sodium excretion (24hUNa), ambulatory BP (ABP) monitoring and blood tests were performed before and after each study phase. The telmisartan-associated increase in PRA was blunted by approximately 50% during salt supplementation compared with placebo; median PRA was 2.3 μg/l/h with placebo compared with 1.7 μg/l/h with salt (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|